About Nuclear pore complex-interacting protein family member B7
Nuclear pore complex-interacting protein family member B7 (NPIPB7) is a protein
from Homo sapiens identified by UniProt accession
O75200, 414 residues long.
MolForge cross-references it against 0 known binders and
37 disease associations.
Target properties
| Protein name | Nuclear pore complex-interacting protein family member B7 |
| UniProt accession | O75200 |
| Gene | NPIPB7 |
| Organism | Homo sapiens |
| Length | 414 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (37)
Diseases linked to this target (Open Targets).
- intelligence · score 0.06
- base metabolic rate measurement · score 0.05
- lean body mass · score 0.05
- alcohol consumption measurement · score 0.05
- type 1 diabetes mellitus · score 0.05
- fat body mass · score 0.05
- BMI-adjusted waist circumference · score 0.04
- obesity · score 0.04
- HbA1c measurement · score 0.04
- bilirubin measurement · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75200-F1 | alphafold | PREDICTED | 53.06 | — |
Amino-acid sequence (414 residues)
MRLRFWLLIW LLLGFISHQP TPVINSLAVY RHRETDFGVG VRDHPGQHGK TPSPQKLDNL IIIIIGFLRR YTFNVLFCTS CLCVSFLKTI FWSRNGHDGS MDVQQRAWRS NRSRQKGLRS ICMHTKKRVS SFRGNKIGLK DVITLRRHVE TKVRAKIRKR KVTTKINRHD KINGKRKTAR KQKMFQRAQE LRRRAEDYHK CKIPPSARKP LCNWVRMAAA EHCHSSGLPY WLYLTAETLK NRMGRQPPPP TQQHSITDNS LSLKTPPECL LTPLPPSVDD NIKECPLAPL PPSPLPPSVD DNLKECLFVP LPPSPLPPSV DDNLKECLFV PLPPSPLPPS VDDNLKTPPL ATQEAEVEKP PKPKRWRVDE VEQSPKPKRQ REAEAQQLPK PKRRRLSKLR TRHCTQAWAI RINP
Explore Nuclear pore complex-interacting protein family member B7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets